Marvell looks set for new all-time highs as heavy call buying signals someone making a massive bet. More than $1.5 million of monthly calls came through in a single day, and the technicals look great. @AdityaInvests90 notes it bounced off its 50 EMA, which last time preceded a 100% move, putting previous highs near $330 in view. x.com  x.com 

A Lumentum deal would put Marvell in a much better competitive position, making its shares an obvious buy here, especially for existing Lumentum shareholders. If the deal breaks, Marvell shares would jump sharply; a moderate premium could mean near-term weakness or sideways trading but would be a great long-term deal. A big premium could push shares down further, though much of that risk is already priced in. x.com  x.com 

Marvell's jump to $290 on its S&P 500 inclusion is a forced institutional pump that looks like a short-term top. Once index funds finish their mechanical rebalancing, that artificial demand dries up and often triggers a sharp sell-the-news flush. The large gap below on the chart acts as a magnet, pointing to a healthy pullback toward the $214-220 zone, where $214 lines up with the 0.786 Fibonacci level. x.com 

Marvell looks interesting at less than 30x calendar-2027 EPS against expected 60-70% annual EPS growth, but overpaying for Lumentum could drive its shares lower. Marvell could pay up to $110B, roughly a 30% premium; the stock-versus-debt mix is unclear, and Lumentum holders might own a third of the combined company. If the deal falls apart, Marvell could rise 10-12%. x.com 

Marvell is a steal at roughly 45x forward free cash flow for a business growing 50%, with a $440 price target by late 2027. It has raised its fiscal 2028 revenue growth outlook to 50%, with roughly $18 billion of revenue now in sight and a credible, clear path to about $5 billion of free cash flow, even though the stock is down more than 25% since June. x.com 

Marvell's potential Lumentum acquisition may fail to increase per-share value because the added profits may not cover dilution and financing costs. A simplified calculation using reported market values implies roughly 38%-45% more shares, requiring about 45% more combined net profit to preserve EPS; debt would add interest and repayment pressure. If the price already reflects future growth, a control premium and possible customer concerns add risk. x.com 

Owning Lumentum's laser fab could secure Marvell's FY28 supply and hedge its DSP franchise as optical links shift to CPO. The rumored deal's strategy makes sense, but short-term pain is likely: at a 30% premium, roughly $17.5B in new debt and the rest in stock, rough math puts EPS dilution near 15%. It turns accretive only if Lumentum outgrows Marvell at today's guided rates for five or six more quarters, which looks achievable while the laser shortage lasts. x.com  x.com  x.com 

Marvell's $70-90 billion FY31 revenue target looks credible: COO Chris Koopmans said key foundry, substrate and packaging suppliers get five-year forecasts and had already seen it before investor day. A $500 price target still looks too aggressive for now; Marvell must show it can grow its networking and photonics segment to deserve a safe price increase. x.com  x.com 

Marvell's run looks like distribution, not accumulation: it doubled in four months on decelerating earnings, spiked on a CEO's compliment and printed its heaviest volume at the top. After Jensen Huang called it the next trillion-dollar company at Computex, it jumped 32% in a day, capping a 105% gain in 18 weeks on record volume of 441 million shares, while EPS growth slowed four straight quarters from 158% to 29%. A 40% collapse from the peak in five weeks followed, the mark of a climax run. … Show more

Marvell's setup played out with a 7% move, and the shares remain worth holding. Gamma positioning shows $240-$250 will be a grind, so near-term upside may stall there. x.com